New HIV-specific company

GSK and Pfizer announce the launch of ViiV Healthcare, a new collaboration that focuses entirely on treatments for HIV. GSK will own 85% of the company, while Pfizer will have a 15% stake. ViiV will offer 10 products currently on the market and invest in innovative research to find even better options for those living with HIV.

Will working together allow these pharmaceutical giants to make faster progress in fighting this devastating virus?

--Jef Akst, Associate Editor, The Scientist